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Detection of inducible clindamycin
resistance (MLSBi) among
methicillin-resistant Staphylococcus
aureus (MRSA) from Libya
M
ethicillin-resistant Staphylococcus aureus
(MRSA) first emerged as nosocomial patho-
gens in the early 1960s are of great concern to
public health and highly reported in human clinical
samples (1). There are major international concerns
about rising levels of MRSA and multi-drug resistant
S. aureus owing to the difficulties of treating infections
and the ease with which MRSA spreads within hospitals
(2). Until recently, most infections of MRSA were
acquired primarily in hospital settings, but now MRSA
is responsible for both hospital and community-acquired
infections (1). The objective of this study was to
investigate MRSA collected isolates for MLSB pheno-
types, in particular inducible clindamycin resistance
(MLSBi).
MRSA collected isolates of hospital-origin were
further investigated at the Microbiology Department,
Biotechnology Research Centre, Tripoli, Libya. One
hundred and twenty-eight MRSA isolates were con-
firmed at species level as S. aureus by culturing onto
mannitol salt agar (MSA) and API Staph test strips
(bioMerieux). Confirmation as MRSA was by latex
agglutination test for PBP2a and disc diffusion method
against cefoxitin in accordance with British Society of
Antimicrobials and Chemotherapy guidelines (BSAC) as
described by Andrews (3). Isolates were also tested
against erythromycin, clindamycin, and synercid for the
characterization of MLSB phenotypic isolates. D-tests
were performed on isolates exhibiting erythromycin
resistance, to assay for the presence of inducible clinda-
mycin resistance (MLSBi phenotype) as described by
Fiebelkorn et al. (4).
Of the 128 tested MRSA isolates, 24.2% (n31)
were resistant to clindamycin, 63.2% (n81) isolates
were resistant to erythromycin, and 17.9% (n23) were
resistant to synercid. Twelve isolates (9.3%) exhibited
MLSBc (constitutive) phenotype and D-tests identified
six isolates (4.6%) with inducible resistance to clindamy-
cin (MLSBi phenotype).
Clindamycin is an efficient and economic lincosamide
drug used for the treatment of staphylococci infection (5).
One macrolide resistance mechanism, modification of a
drug binding site on the ribosome, results in resistance to
macrolides, azalides, lincosamides, and group (B) strep-
togramins (MLSB). MLSB phenotypes can be either
constitutive (MLSBc) or inducible (MLSBi). The induci-
ble resistance to clindamycin (MLSBi) in MRSA can
severely compromise therapy and can result in failure of
clindamycin treatment of MRSA infections when non-
suitable therapy (e.g. erythromycin) is given (6). MLSBi
strains can be successfully treated with clindamycin;
however MLSBi can complicate therapy when MLSBi
phenotype-switching into MLSBc occurs possibly due to
mutation, in the absence of macrolide inducers (6).
Clindamycin can still be used for MRSA infections in
our hospitals. (7) However, susceptibility testing for the
detection of inducible resistance to clindamycin should be
routinely performed (7, 8).
Acknowledgements
Thanks to Dr. Mohamed El Sherif the director of National
Authority for Scientiﬁc Research, Tripoli, Libya for the unlimited
support and Dr. Keith E. Baptiste from the University of Copenha-
gen, Denmark.
Mohamed O. Ahmed
Department of Microbiology
Biotechnology Research Centre
Tripoli, Libya
and
Department of Veterinary Microbiology and
Parasitology
Faculty of Veterinary Medicine
AlFateh University
Tripoli, Libya
Email: mhmd73@lttnet.net
Mohamed H. Alghazali and Abdelalbaset R. Abuzweda
Department of Microbiology
Biotechnology Research Centre
Tripoli, Libya
Samira G. Amri
Burns and Plastic Surgery Centre
Tripoli, Libya
(page number not for citation purpose)
 LETTER TO THE EDITOR
Libyan J Med 2010. # 2010 M.O. Ahmed et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution-
Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction
in any medium, provided the original work is properly cited.
1
Citation: Libyan J Med 2010, 5: 4636 - DOI: 10.3402/ljm.v5i0.4636References
1. Robinson JO, Pearson JC, Christiansen KJ, Coombs GW,
Murray RJ. Community-associated versus healthcare-associated
methicillin-resistant Staphylococcus aureus bacteraemia: a 10-
year retrospective review. Eur J Clin Microbiol Infect Dis. 2009;
28: 35361.
2. Gould IM. The clinical signiﬁcance of methicillin-resistant
Staphylococcus aureus. J Hosp Infect. 2005; 61: 27782.
3. Andrews JM. BSAC standardized disc susceptibility testing
method (version 5). J Antimicrob Chemother. 2006; 58: 51129.
4. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH.
Practical disk diffusion method for detection of inducible
clindamycin resistance in Staphylococcus aureus and coagulase-
negative staphylococci. J Clin Microbiol. 2003; 41: 47404.
5. Oguz VA, Yapar N, Sezak N, Cavus SA, Kurutepe S, Peksel H,
et al. The rate of inducible clindamycin resistance and suscept-
ibilities to other antimicrobial agents in staphylococci. Mikro-
biyol Bul. 2009; 43: 3744.
6. Lewis JS, Jorgensen JH. Inducible clindamycin resistance in
Staphylococci: should clinicians and microbiologists be con-
cerned? Clin Infect Dis. 2005; 40: 2805.
7. El-Bouri K. Clinical microbiology services are essential for
diagnosis, treatment and prevention of MRSA and other
nosocomial pathogens in Libyan healthcare facilities. Libyan J
Med. 2009; 4: 1289.
8. Zorgani A, Shawerf O, Tawil K, El-Turki E, Ghenghesh KS.
Inducible clindamycin resistance among staphylococci isolated
from burn patients. Libyan J Med. 2009; 4: 14952.
Letter to the Editor
2
(page number not for citation purpose)
Citation: Libyan J Med 2010, 5: 4636 - DOI: 10.3402/ljm.v5i0.4636